ResMed reported $1.32B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Ansell USD 468.9M 53.1M Dec/2025
Artivion USD 76.66M 30.28M Sep/2026
AtriCure USD 83.97M 2.06M Sep/2026
Baxter International USD 3.81B 218M Sep/2026
Cochlear AUD 558.9M 43.4M Dec/2025
Cooper Companies USD 1.87B 61.9M Jun/2026
CSL USD 4.61B 207M Dec/2025
Dexcom USD 2.25B 105.1M Sep/2026
Edwards Lifesciences USD 1.58B 68.8M Sep/2026
Fisher Paykel Healthcare NZD 497.8M 26.5M Jun/2026
Globus Medical USD 507.94M 28.59M Sep/2026
Haemonetics USD 300.84M 37.6M Sep/2026
Idexx Laboratories USD 1.26B 23.44M Sep/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 814.4M 70.2M Sep/2026
Integra LifeSciences USD 329M 1.88M Sep/2026
Intuitive Surgical USD 3.23B 652.4M Sep/2026
Medtronic USD 11.8B 141M Jun/2026
Philips EUR 7.91B 485M Sep/2026
Ramsay Health Care AUD 3.95B 514.2M Dec/2025
ResMed USD 1.32B 70.89M Sep/2026
Sigma Healthcare AUD 1.7B 1.33B Dec/2025
Sonic Healthcare AUD 2.23B 92.84M Dec/2024
Steris USD 1.21B 75.5M Sep/2026
Teleflex USD 917.1M 196.72M Sep/2026
Thermo Fisher Scientific USD 14.17B 899M Sep/2026